Chemed Co. (NYSE:CHE) insider Kevin J. Mcnamara sold 827 shares of the business’s stock in a transaction that occurred on Friday, November 9th. The shares were sold at an average price of $315.74, for a total value of $261,116.98. Following the completion of the sale, the insider now owns 122,308 shares of the company’s stock, valued at approximately $38,617,527.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

NYSE:CHE opened at $307.14 on Wednesday. The company has a market capitalization of $5.01 billion, a PE ratio of 27.55, a P/E/G ratio of 2.74 and a beta of 1.23. The company has a current ratio of 1.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.23. Chemed Co. has a 12-month low of $227.14 and a 12-month high of $335.99.

Chemed (NYSE:CHE) last released its earnings results on Monday, October 29th. The company reported $3.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.80 by $0.27. The business had revenue of $444.15 million for the quarter, compared to analyst estimates of $445.16 million. Chemed had a return on equity of 35.13% and a net margin of 11.73%. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.15 earnings per share. Equities analysts predict that Chemed Co. will post 11.41 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Monday, November 12th will be issued a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date is Thursday, November 8th. Chemed’s payout ratio is currently 22.39%.

CHE has been the subject of a number of research reports. Zacks Investment Research reiterated a “buy” rating and issued a $342.00 price objective on shares of Chemed in a research note on Monday. Bank of America initiated coverage on Chemed in a research note on Friday, October 12th. They issued a “buy” rating and a $390.00 price objective for the company. Royal Bank of Canada boosted their price objective on Chemed to $321.00 and gave the company a “market perform” rating in a research note on Monday, July 30th. Finally, ValuEngine cut Chemed from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 2nd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $332.00.

Several large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its holdings in shares of Chemed by 69.5% in the third quarter. Renaissance Technologies LLC now owns 233,690 shares of the company’s stock valued at $74,683,000 after purchasing an additional 95,790 shares during the period. Riverhead Capital Management LLC increased its holdings in shares of Chemed by 22.5% in the third quarter. Riverhead Capital Management LLC now owns 1,636 shares of the company’s stock valued at $523,000 after purchasing an additional 300 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp acquired a new position in shares of Chemed in the third quarter valued at approximately $4,794,000. Tower Research Capital LLC TRC increased its holdings in shares of Chemed by 303.3% in the third quarter. Tower Research Capital LLC TRC now owns 2,194 shares of the company’s stock valued at $701,000 after purchasing an additional 1,650 shares during the period. Finally, Allianz Asset Management GmbH increased its holdings in shares of Chemed by 3,298.7% in the third quarter. Allianz Asset Management GmbH now owns 51,083 shares of the company’s stock valued at $16,325,000 after purchasing an additional 49,580 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Kevin J. Mcnamara Sells 827 Shares of Chemed Co. (CHE) Stock” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2018/11/14/kevin-j-mcnamara-sells-827-shares-of-chemed-co-che-stock.html.

About Chemed

Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

Further Reading: Why is Cost of Capital Important?

Insider Buying and Selling by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.